Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Harbour BioMed Starts Phase III Trial of mAb for Myasthenia Gravis

publication date: Sep 27, 2021

Harbour BioMed has dosed the first patient in a China Phase III trial of its anti-FcRn antibody as a therapy for myasthenia gravis. In its Phase II proof -of-concept test, batoclimab showed statistically significant improvement in efficacy as well as a favorable safety and tolerability profile. HBM is developing batoclimab as a pipeline-in-a-product to treat multiple pathogenic-IgG mediated autoimmune diseases. Earlier this year, the candidate was granted Breakthrough Therapy Designation in China. HBM's business office is in Boston with drug discovery operations in Rotterdam and labs in Shanghai. More details....

Stock Symbol: (HK: 02142)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.